HUE051067T2 - N-szulfonilezett pirazolo[3,4-b]piridin-6-karboxamidok és alkalmazási módszereik - Google Patents

N-szulfonilezett pirazolo[3,4-b]piridin-6-karboxamidok és alkalmazási módszereik

Info

Publication number: HUE051067T2
Authority: HU; Hungary
Prior art keywords: sulfonylated; carboxamides; pyrazolo; pyridine; administration
Prior art date: 2015-10-09

Application number

HUE16788232A

Other languages

English (en)

Inventor

Rhalid Akkari

Original Assignee

Abbvie Overseas Sarl

Galapagos Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-10-09

Filing date

2016-10-07

Publication date

2021-01-28

2016-10-07 Application filed by Abbvie Overseas Sarl, Galapagos Nv filed Critical Abbvie Overseas Sarl

2021-01-28 Publication of HUE051067T2 publication Critical patent/HUE051067T2/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

HUE16788232A 2015-10-09 2016-10-07 N-szulfonilezett pirazolo[3,4-b]piridin-6-karboxamidok és alkalmazási módszereik HUE051067T2 (hu)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562239647P	2015-10-09	2015-10-09
US201662309794P	2016-03-17	2016-03-17

Publications (1)

Publication Number	Publication Date
HUE051067T2 true HUE051067T2 (hu)	2021-01-28

Family

ID=57209654

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE16788232A HUE051067T2 (hu)	2015-10-09	2016-10-07	N-szulfonilezett pirazolo[3,4-b]piridin-6-karboxamidok és alkalmazási módszereik

Country Status (32)

Country	Link
US (4)	US9890158B2 (hu)
EP (1)	EP3359541B1 (hu)
JP (1)	JP6779992B2 (hu)
KR (1)	KR20180083323A (hu)
CN (1)	CN108513574B (hu)
AU (1)	AU2016333856C1 (hu)
BR (1)	BR112018007161B1 (hu)
CA (1)	CA3001096A1 (hu)
CL (1)	CL2018000911A1 (hu)
CO (1)	CO2018003716A2 (hu)
CR (1)	CR20180215A (hu)
CY (1)	CY1123545T1 (hu)
DK (1)	DK3359541T3 (hu)
EC (1)	ECSP18032223A (hu)
ES (1)	ES2829636T3 (hu)
HR (1)	HRP20201618T1 (hu)
HU (1)	HUE051067T2 (hu)
IL (1)	IL258553A (hu)
LT (1)	LT3359541T (hu)
MX (1)	MX379276B (hu)
NZ (1)	NZ741223A (hu)
PE (1)	PE20181348A1 (hu)
PH (1)	PH12018500765B1 (hu)
PL (1)	PL3359541T3 (hu)
PT (1)	PT3359541T (hu)
RU (1)	RU2724345C2 (hu)
SG (1)	SG11201802932VA (hu)
SI (1)	SI3359541T1 (hu)
TW (1)	TWI720032B (hu)
UY (1)	UY36943A (hu)
WO (1)	WO2017060874A1 (hu)
ZA (1)	ZA201802976B (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3001096A1 (en) *	2015-10-09	2017-04-13	Abbvie S.A.R.L.	N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
US10138227B2 (en)	2016-06-03	2018-11-27	Abbvie S.Á.R.L.	Heteroaryl substituted pyridines and methods of use
US10399940B2 (en)	2016-10-07	2019-09-03	Abbvie S.Á.R.L.	Substituted pyrrolidines and methods of use
US9981910B2 (en)	2016-10-07	2018-05-29	Abbvie S.Á.R.L.	Substituted pyrrolidines and methods of use
EP3558982A1 (en)	2016-12-20	2019-10-30	AbbVie S.À.R.L.	Deuterated cftr modulators and methods of use
TW201831471A (zh)	2017-02-24	2018-09-01	盧森堡商艾伯維公司	囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
US10988454B2 (en) *	2017-09-14	2021-04-27	Abbvie Overseas S.À.R.L.	Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019193062A1 (en)	2018-04-03	2019-10-10	Abbvie S.Á.R.L	Substituted pyrrolidines and their use
GB201905711D0 (en) *	2019-04-24	2019-06-05	Galapagos Nv	Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
EP3747882A1 (en)	2019-06-03	2020-12-09	AbbVie Overseas S.à r.l.	Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
CN114761383A (zh) *	2019-06-12	2022-07-15	诺瑟拉有限公司	磺酰胺衍生物及其用途
TW202115014A (zh)	2019-07-12	2021-04-16	美商奧佛麥德公司	用於治療囊腫纖維化之化合物
PH12022551119A1 (en)	2019-12-10	2023-08-23	Hoffmann La Roche	New methylquinazolinone derivatives
CN115843272A (zh)	2020-05-08	2023-03-24	哈利亚治疗公司	Nek7激酶的抑制剂
JP2023528659A (ja)	2020-06-08	2023-07-05	ハリア・セラピューティクス・インコーポレイテッド	Ｎｅｋ７キナーゼの阻害剤
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
MX2023001993A (es)	2020-08-20	2023-02-27	Univ Leland Stanford Junior	Metodos para tratar enfermedades respiratorias caracterizados por hipersecrecion de mucosidad.
US20220213041A1 (en)	2021-01-06	2022-07-07	AbbVie Global Enterprises Ltd.	Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
US20220211692A1 (en)	2021-01-06	2022-07-07	AbbVie Global Enterprises Ltd.	Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
KR20240155228A (ko)	2022-02-03	2024-10-28	버텍스 파마슈티칼스 인코포레이티드	(6a,12a)-17-아미노-12-메틸-6,15-비스(트리플루오로메틸)-13,19-디옥사-3,4,18-트리아자트리시클로[12.3.1.12,5]노나데카-1(18),2,4,14,16-펜타엔-6-올의 결정질 형태를 제조하는 방법
EP4472635A1 (en)	2022-02-03	2024-12-11	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
CN118974059A (zh)	2022-02-08	2024-11-15	弗特克斯药品有限公司	囊性纤维化跨膜传导调控因子的调节剂
WO2023224931A1 (en)	2022-05-16	2023-11-23	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
CN115806532A (zh) *	2022-08-31	2023-03-17	大连百傲化学股份有限公司	一种mit中杂质的制备方法
WO2024059200A1 (en)	2022-09-14	2024-03-21	Halia Therapeutics, Inc.	Nek7 inhibitors
CN115960100B (zh) *	2022-12-28	2023-08-18	北京康立生医药技术开发有限公司	一种治疗胃肠道间质瘤药物皮咪特昔布的合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3833598A (en) *	1972-12-29	1974-09-03	Squibb & Sons Inc	Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
GB0217431D0 (en)	2002-07-27	2002-09-04	Astrazeneca Ab	Novel compounds
BRPI0508843A (pt) *	2004-03-16	2007-08-28	Glaxo Group Ltd	composto ou sal do mesmo, método para preparar um composto ou um sal do mesmo, método de tratamento e/ou profilaxia de doença, e, composição farmacêutica
US7939558B2 (en)	2004-06-04	2011-05-10	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
DK2502911T3 (en)	2004-06-24	2017-06-06	Vertex Pharma	Modulators of ATP-binding cassette transporters
US8354427B2 (en)	2004-06-24	2013-01-15	Vertex Pharmaceutical Incorporated	Modulators of ATP-binding cassette transporters
ATE415400T1 (de) *	2004-07-05	2008-12-15	Astellas Pharma Inc	Pyrazolopyridinderivate
US8362031B2 (en) *	2004-08-20	2013-01-29	University Of Kansas	Lonidamine analogues and treatment of polycystic kidney disease
WO2008147952A1 (en)	2007-05-25	2008-12-04	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CN101917999A (zh) *	2007-11-07	2010-12-15	弗尔德里克斯制药股份有限公司	蛋白质运输的调节
PT2444120T (pt)	2007-12-10	2018-01-03	Novartis Ag	Análogos da amilorida espirocíclicos como bloqueadores de enac
WO2009076593A1 (en)	2007-12-13	2009-06-18	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CA2741178A1 (en)	2008-10-23	2010-04-29	Vertex Pharmaceuticals Incorporated	Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
JP5699090B2 (ja)	2008-12-30	2015-04-08	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
SI2616444T1 (sl) *	2010-09-14	2016-03-31	Instytut Biochemii I Biofizyki Pan	Spojine kot modulatorji mutantnega cftr proteina in njihova uporaba za zdravljenje bolezni, povezanih s cftr proteinsko okvaro
EP2624695B1 (en)	2010-10-08	2015-09-23	Nivalis Therapeutics, Inc.	Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors
JP6165733B2 (ja)	2011-09-16	2017-07-19	ノバルティスアーゲー	Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038373A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
WO2013038381A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine/pyrazine amide derivatives
WO2013038378A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
US9034879B2 (en)	2011-09-16	2015-05-19	Novartis Ag	Heterocyclic compounds for the treatment of CF
HUE041740T2 (hu)	2011-09-20	2019-05-28	Univ North Carolina Chapel Hill	Nátriumcsatornák szabályozása PLUNC-fehérjékkel
US9630929B2 (en) *	2011-10-31	2017-04-25	Xenon Pharmaceuticals Inc.	Benzenesulfonamide compounds and their use as therapeutic agents
AU2013348018A1 (en) *	2012-11-20	2015-06-04	Discoverybiomed, Inc.	Small molecule CFTR correctors
CA3122383A1 (en)	2013-05-07	2014-11-13	Galapagos Nv	Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis.
ES2691944T3 (es)	2013-08-08	2018-11-29	Galapagos Nv	Tieno[2,3-c]piranos como moduladores CFTR
AU2015214366B2 (en) *	2014-02-06	2019-04-18	Abbvie, Inc.	6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
AU2015229117A1 (en)	2014-03-13	2016-09-29	Proteostasis Therapeutics, Inc.	Compounds, compositions, and methods for increasing CFTR activity
AU2015229188A1 (en)	2014-03-13	2016-09-29	Proteostasis Therapeutics, Inc.	Compounds, compositions, and methods for increasing CFTR activity
CA2965981C (en)	2014-10-31	2023-04-25	Abbvie S.A.R.L.	Substituted chromanes and method of use
WO2016069891A1 (en)	2014-10-31	2016-05-06	Abbvie Inc.	Substituted tetrahydropyrans and method of use
AU2016333907A1 (en) *	2015-10-09	2018-04-12	AbbVie S.à.r.l.	Novel compounds for treatment of cystic fibrosis
CA3001096A1 (en) *	2015-10-09	2017-04-13	Abbvie S.A.R.L.	N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use

2016
- 2016-10-07 CA CA3001096A patent/CA3001096A1/en active Pending
- 2016-10-07 AU AU2016333856A patent/AU2016333856C1/en active Active
- 2016-10-07 KR KR1020187012937A patent/KR20180083323A/ko not_active Ceased
- 2016-10-07 JP JP2018517444A patent/JP6779992B2/ja active Active
- 2016-10-07 CN CN201680069459.4A patent/CN108513574B/zh active Active
- 2016-10-07 ES ES16788232T patent/ES2829636T3/es active Active
- 2016-10-07 LT LTEP16788232.3T patent/LT3359541T/lt unknown
- 2016-10-07 PE PE2018000521A patent/PE20181348A1/es unknown
- 2016-10-07 CR CR20180215A patent/CR20180215A/es unknown
- 2016-10-07 HU HUE16788232A patent/HUE051067T2/hu unknown
- 2016-10-07 PT PT167882323T patent/PT3359541T/pt unknown
- 2016-10-07 US US15/287,911 patent/US9890158B2/en active Active
- 2016-10-07 DK DK16788232.3T patent/DK3359541T3/da active
- 2016-10-07 MX MX2018004359A patent/MX379276B/es unknown
- 2016-10-07 NZ NZ741223A patent/NZ741223A/en unknown
- 2016-10-07 EP EP16788232.3A patent/EP3359541B1/en active Active
- 2016-10-07 WO PCT/IB2016/056029 patent/WO2017060874A1/en active Application Filing
- 2016-10-07 PL PL16788232T patent/PL3359541T3/pl unknown
- 2016-10-07 SG SG11201802932VA patent/SG11201802932VA/en unknown
- 2016-10-07 BR BR112018007161-7A patent/BR112018007161B1/pt active IP Right Grant
- 2016-10-07 SI SI201630965T patent/SI3359541T1/sl unknown
- 2016-10-07 RU RU2018115722A patent/RU2724345C2/ru active
- 2016-10-07 TW TW105132676A patent/TWI720032B/zh not_active IP Right Cessation
- 2016-10-11 UY UY0001036943A patent/UY36943A/es not_active Application Discontinuation
2017
- 2017-12-15 US US15/843,917 patent/US10259810B2/en active Active
2018
- 2018-04-06 PH PH12018500765A patent/PH12018500765B1/en unknown
- 2018-04-06 CO CONC2018/0003716A patent/CO2018003716A2/es unknown
- 2018-04-08 IL IL258553A patent/IL258553A/en active IP Right Grant
- 2018-04-09 CL CL2018000911A patent/CL2018000911A1/es unknown
- 2018-04-26 EC ECIEPI201832223A patent/ECSP18032223A/es unknown
- 2018-05-07 ZA ZA2018/02976A patent/ZA201802976B/en unknown
2019
- 2019-03-06 US US16/293,973 patent/US20190202823A1/en not_active Abandoned
- 2019-06-18 US US16/444,495 patent/US10647717B2/en active Active
2020
- 2020-10-08 HR HRP20201618TT patent/HRP20201618T1/hr unknown
- 2020-11-03 CY CY20201101034T patent/CY1123545T1/el unknown

Also Published As

Publication number	Publication date
PE20181348A1 (es)	2018-08-22
AU2016333856B2 (en)	2021-05-20
PL3359541T3 (pl)	2021-01-11
CY1123545T1 (el)	2022-03-24
DK3359541T3 (da)	2020-11-09
US20170101405A1 (en)	2017-04-13
US20190330207A1 (en)	2019-10-31
KR20180083323A (ko)	2018-07-20
TW201722948A (zh)	2017-07-01
PH12018500765B1 (en)	2020-11-25
MX379276B (es)	2025-03-10
CN108513574B (zh)	2021-01-05
UY36943A (es)	2017-05-31
ES2829636T3 (es)	2021-06-01
ECSP18032223A (es)	2018-05-31
AU2016333856C1 (en)	2021-12-09
BR112018007161B1 (pt)	2024-01-16
CA3001096A1 (en)	2017-04-13
JP2018529743A (ja)	2018-10-11
RU2018115722A (ru)	2019-11-12
CO2018003716A2 (es)	2018-07-19
PT3359541T (pt)	2020-11-11
CR20180215A (es)	2018-06-05
HRP20201618T1 (hr)	2020-12-25
LT3359541T (lt)	2020-11-25
US10259810B2 (en)	2019-04-16
US9890158B2 (en)	2018-02-13
US20180105522A1 (en)	2018-04-19
MX2018004359A (es)	2018-05-01
TWI720032B (zh)	2021-03-01
CL2018000911A1 (es)	2018-08-24
EP3359541A1 (en)	2018-08-15
WO2017060874A1 (en)	2017-04-13
JP6779992B2 (ja)	2020-11-04
US20190202823A1 (en)	2019-07-04
SG11201802932VA (en)	2018-05-30
ZA201802976B (en)	2019-07-31
BR112018007161A2 (pt)	2018-10-30
US10647717B2 (en)	2020-05-12
PH12018500765A1 (en)	2018-10-01
RU2724345C2 (ru)	2020-06-23
CN108513574A (zh)	2018-09-07
NZ741223A (en)	2023-03-31
SI3359541T1 (sl)	2021-01-29
IL258553A (en)	2018-05-31
AU2016333856A1 (en)	2018-04-26
EP3359541B1 (en)	2020-08-05
RU2018115722A3 (hu)	2020-02-18

Publication	Publication Date	Title
HUE051067T2 (hu)	2021-01-28	N-szulfonilezett pirazolo[3,4-b]piridin-6-karboxamidok és alkalmazási módszereik
HK1255566A1 (zh)	2019-08-23	氧代吡啶酰胺類衍生物、其製備方法及其在醫藥上的應用
PT3546457T (pt)	2021-08-06	Derivado de pirazolo-heteroarílico, método de preparação e a utilização médica do mesmo
HUE054103T2 (hu)	2021-08-30	Izokinolin-3-il-karboxamidok, ezek elõállítása és alkalmazása
HK1232140A1 (zh)	2018-01-05	微類器官以及製造和使用它們的方法
HUE037558T2 (hu)	2018-09-28	Imidazo[4,5-c]kinolin-2-on vegyületek és alkalmazásuk rák kezelésében
HUE051877T2 (hu)	2021-03-29	Biciklusos származékok, eljárás elõállításukra és ezeket tartalmazó gyógyszerészeti készítmények
FR22C1058I2 (fr)	2023-11-17	Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide
HUE049014T2 (hu)	2020-09-28	Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére
EP3494213A4 (en)	2020-01-08	MODEL FOR BLOOD BRAIN CABINETS AND METHOD FOR THE PRODUCTION AND USE THEREOF
HK1254055A1 (zh)	2019-07-12	製備奧貝膽酸及其衍生物的方法
ZA201901861B (en)	2020-10-28	Fused tricyclic ?-amino acid derivative, preparation method therefor, and medical use thereof
EP3452481A4 (en)	2020-02-26	IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS
EP3144292A4 (en)	2018-01-17	2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof
EP3373910A4 (en)	2019-06-12	ECHINOMYCIN FORMULATION, METHOD FOR MANUFACTURING THE SAME, AND METHOD OF USING THE SAME
HK1225723A1 (zh)	2017-09-15	取代的咪唑並[1，2-a]吡啶甲酰胺及其用途
IL257763B (en)	2021-05-31	Genetically modified cells that are resistant to drugs and methods for their use
PT3398598T (pt)	2022-07-12	Derivado de sulfonamida e método de preparação e utilização do mesmo
HK1246279A1 (zh)	2018-09-07	C14-位羥基酯化的雷公藤甲素氨基酸衍生物、及其製備方法和應用
PL3723807T3 (pl)	2022-01-24	Leczenie skojarzone obejmujące podawanie 1h-pirazolo[4,3-b]pirydyn
IL262405A (en)	2018-12-31	Methods for preparing obeticholic acid and its derivatives
PL3360863T3 (pl)	2022-08-08	Pochodna i związek pośredni etomidatu, sposób przygotowania i zastosowanie
LT3230289T (lt)	2019-10-10	7-(morfolinil)-2-(n-piperazinil)metiltieno[2, 3-c]piridino dariniai kaip priešvėžiniai vaistai
EP3275881A4 (en)	2018-09-12	Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heterooxy, preparation method thereof and pharmaceutical use thereof
EP3381921A4 (en)	2019-10-30	GINKGOLIDE B DERIVATIVE AND METHOD OF PREPARING THEREOF AND USE THEREOF